introduction
Our team has worked for years to create an efficient way to discover new chemistry, naturally made by microbes.
We believe that most of undiscovered compounds produced by microbes will be identified and made accessible to life science R&D organizations around the world, helping humans and enriching life.
We aim to scale our discovery platform to identify hundreds of new compounds within the next few years. We believe that this could give access to life science companies of all sizes to license and develop these new compounds into economically valuable and environmentally friendly products.
We envision licensing our natural products to companies such as:
- Agriculture: Valent, Bayer, FMC, UPL, Corteva, Syngenta, Sumitomo
- Animal Health: Elanco, BiomEdit, Zoetis, Boehringer Ingelheim
- Pharmaceutical: Roche, Janssen, Novartis, Merck, AstraZeneca,Pfizer
We plan to continue growing our collection of natural products so that our consumers may have access to new licenses year after year.
success to date
- Seven peer-reviewed publications identifying new molecules discovered using the MGx platform.
- Investigated/discovered new molecules for clients in the agriculture and animal health industries (Corteva, Valent, Elanco).
- $400k angel investment in 2020.
- License for MGX-1001, a promising new herbicide with the potential to be the first new mechanism of action broad spectrum herbicide in 35 years (US Provisional Patent Applications #63/075138 and #63/181,745, PCT Patent Application #PCT/US2021/048904).
- One of six finalists in the 2022 $1M Radicle Growth-UPL Challenge.
- Self-built library containing over 2500 isolated microbial strains.
problem
Over half of all small molecule medicines (e.g. penicillin, Lipitor) and many crop protection products (e.g. glufosinate) come from natural sources. Recent estimates suggest that 97% of all naturally produced chemicals remain undiscovered.
Many life science companies have abandoned their research and discovery platforms surrounding bacterial and fungal natural products because of low success rates and high costs. Classical discovery methods have provided diminishing returns due to the constant issue of rediscovering already known chemicals.
MicroMGx aims to change all that using the MGx discovery platform.
solution
The MGx platform technology discovers new chemistry by harnessing the power of the world’s best chemists: microbes. Microbes have been creating and modifying chemicals to do specific tasks for over 4 billion years.
Our team has worked for 10 years to develop the optimal method for exploring and finding new naturally made chemicals.
The MGx platform integrates DNA sequencing, high-resolution mass spectrometry, and bioinformatics to discover microbes that produce new chemicals. Then, we aim to quickly test for what we are looking for – natural herbicides, cancer therapeutics, antibiotics, insecticides, and more. We hope to cut the cost and time of discovery of classical methods by approximately 1/100th, potentially allowing us to scale up our operation.

frequently asked questions
business model
MicroMGx is a discovery and licensing company.
Our Process:
- Discover new molecules made by microbes using the MGx discovery platform.
- Test for bioactivity in targeted field/industry.
- Patent the novel molecule and its applications.
- License our new molecules to uniquely qualified life science companies looking to develop a new product.
Using the MGx platform, we aim to discover new molecules and hope to give the world access to natural medicines and agricultural products still waiting to be discovered.

Licensing would involve an upfront fee to MicroMGx, milestone payments once a customer successfully reaches a development milestone with our chemical, and then, once launched, royalties may flow back to MicroMGx.
market

Our global market is every life science company, large or small, that wants to augment their R&D pipeline. For instance, a mid-sized pharmaceutical may want to license a novel anti-cancer compound from us because of its activity against brain cancer. This may increase their pipeline of new drugs and may supplement their anti-cancer effort. In 2019, Clarivate produced a report of discovery deals from which this diagram was developed.
press
- EIN Press Wire
The Radicle Carbon & Soil Challenge by UPL announces its finalists - BusinessWire
MicroMGx Platform to Support New Study Aimed at New Natural Product Discovery - MicroMGx
MicroMGx partners with Corteva Agriscience to Expand Use of Natural Products Discovery for Crop Protection
MicroMGx announces research collaboration agreement with Elanco to investigate animal-health promoting microorganisms
team






Use of Proceeds
If the offering's maximum amount of $1,069,998 is raised:
Use | Value | % of Proceeds |
---|---|---|
Compensation for managers | $136,568 | 12.8% |
Platform Costs | $600,000 | 56.1% |
Testing MGX 1001 | $150,000 | 14.0% |
Rent | $36,000 | 3.4% |
Structure Isolation | $60,000 | 5.6% |
Additional Equipment | $35,000 | 3.3% |
Intermediary fees | $52,430 | 4.9% |
Terms
This is an offering of Common Stock, under registration exemption 4(a)(6), in MicroMGx, Inc., doing business as MicroMGx Inc. This offering must raise at least $10,000 by March 31, 2023 at 5:55pm ET. If this offering doesn’t reach its target, then your money will be refunded. MicroMGx Inc may issue additional securities to raise up to $1,069,998, the offering’s maximum.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Pitch Deck
Financials
MicroMGx Inc’s official name is MicroMGx, Inc., so that’s the name that appears in the statements below.
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
- Jan 25, 2023MicroMGx is excited to announce that we have...
- Nov 25, 2022As CEO of MicroMGx, I wanted to let our...
- Oct 23, 2022We at MicroMGx are very happy and proud to...
- Oct 13, 2022The leadership team at MicroMGx would like to...
- Sep 22, 2022It is starting to get exciting! I have...
- Sep 14, 2022We have just started on this 2 month journey to...
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.